Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Apr;56(4):984-6.
doi: 10.1128/iai.56.4.984-986.1988.

Anticapsular antibody requirements for protection against experimental Haemophilus influenzae type b bacteremia after splenectomy

Affiliations

Anticapsular antibody requirements for protection against experimental Haemophilus influenzae type b bacteremia after splenectomy

L G Rubin. Infect Immun. 1988 Apr.

Abstract

Although asplenic individuals are at higher risk for infection with encapsulated bacteria, it is not known whether they require a higher concentration of anticapsular antibody than normal individuals do for protection against invasive disease caused by Haemophilus influenzae type b. At 21 days of age, rats were passively immunized with human hyperimmune serum globulin against H. influenzae b polysaccharide (or saline) after recovery from splenectomy or a sham operation. Starting at 18 h after immunization, rats received three intranasal inoculations of 10(7) CFU of H. influenzae b over the next 24 h. Of sham-operated rats given 0.75 or 3.0 micrograms of anticapsular antibody, 91 or 96%, respectively, were protected from bacteremia, whereas only 59 and 67% of similarly treated asplenic rats were protected (P less than 0.004, control versus asplenic rats). A 12-microgram antibody dose resulted in the complete protection of both groups. The magnitude of bacteria was significantly higher in the asplenic group at each dose of antibody. Thus, asplenic hosts may require a higher concentration of anticapsular antibody than normal individuals do for protection against invasive H. influenzae b disease.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Infect Dis. 1988 Jan;157(1):85-90 - PubMed
    1. J Infect Dis. 1977 Feb;135(2):303-7 - PubMed
    1. Infect Immun. 1980 Mar;27(3):872-5 - PubMed
    1. Infect Immun. 1983 Feb;39(2):709-14 - PubMed
    1. J Clin Invest. 1971 Apr;50(4):734-43 - PubMed

Publication types

Substances